CNTA is no longer actively traded. Data shown reflects verified historical relationships.
0Suppliers
2Customers
2Debt Items
11Related Chains

Centessa Pharmaceuticals plc Suppliers

No suppliers on recordCentessa Pharmaceuticals plc has not yet been matched to upstream suppliers in our database, or is still being processed.

Centessa Pharmaceuticals plc Customers

TickerNameConfidenceEvidence
GENMAB-A-S GENMAB-A-S 92% the Company granted to Genmab an exclusive worldwide license to leverage its proprietary LockBody technology platform
GNMSF Genmab A/S 92% Reciprocal relationship from GNMSF graph: Reciprocal relationship from CNTA graph: the Company granted to Genmab an exclusive worldwide license to leverage its proprietary LockBody technology platform

Centessa Pharmaceuticals plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
CNTA-DEBT-8755 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-12-31.
CNTA-DEBT Debt stack $117.8M 90% Market cache reports total debt of $117.8M.

Centessa Pharmaceuticals plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Centessa Pharmaceuticals plc.

Centessa Pharmaceuticals plc Ownership

HolderNameConfidenceEvidence
CNTA-OWNER-TCG-CROSSOVER-MANAGEMENT-LLC TCG Crossover Management, LLC 95% 13F/ownership overlay lists TCG Crossover Management, LLC; shares held 4,286,480; ownership 2.93%; value $118.2M; as of 2025-12-31.
CNTA-OWNER-INDEX-VENTURE-LIFE-ASSOCIATES-VI-LTD Index Venture Life Associates VI Ltd 95% 13F/ownership overlay lists Index Venture Life Associates VI Ltd; shares held 9,961,789; ownership 6.82%; value $274.7M; as of 2025-12-31.
CNTA-OWNER-GENERAL-ATLANTIC-L-P General Atlantic, L.P. 95% 13F/ownership overlay lists General Atlantic, L.P.; shares held 6,117,715; ownership 4.19%; value $168.7M; as of 2025-12-31.
CNTA-OWNER-JANUS-HENDERSON-GROUP-PLC Janus Henderson Group PLC 95% 13F/ownership overlay lists Janus Henderson Group PLC; shares held 4,093,608; ownership 2.80%; value $112.9M; as of 2025-12-31.
CNTA-OWNER-FMR-LLC FMR, LLC 95% 13F/ownership overlay lists FMR, LLC; shares held 8,961,939; ownership 6.14%; value $247.2M; as of 2025-12-31.
CNTA-OWNER-MEDICXI-VENTURES-MANAGEMENT-JERSEY-LTD Medicxi Ventures Management (Jersey) Ltd 95% 13F/ownership overlay lists Medicxi Ventures Management (Jersey) Ltd; shares held 19,963,157; ownership 13.67%; value $550.6M; as of 2025-12-31.
CNTA-OWNER-SIREN-L-L-C Siren, L.L.C. 95% 13F/ownership overlay lists Siren, L.L.C.; shares held 4,027,517; ownership 2.76%; value $111.1M; as of 2025-12-31.
CNTA-OWNER-ADAGE-CAPITAL-PARTNERS-GP-L-L-C Adage Capital Partners GP L.L.C. 95% 13F/ownership overlay lists Adage Capital Partners GP L.L.C.; shares held 11,281,741; ownership 7.72%; value $311.2M; as of 2025-12-31.
CNTA-OWNER-FARALLON-CAPITAL-MANAGEMENT-LLC Farallon Capital Management LLC 95% 13F/ownership overlay lists Farallon Capital Management LLC; shares held 5,377,068; ownership 3.68%; value $148.3M; as of 2025-12-31.
CNTA-OWNER-AVORO-CAPITAL-ADVISORS-LLC Avoro Capital Advisors LLC 95% 13F/ownership overlay lists Avoro Capital Advisors LLC; shares held 14,555,555; ownership 9.97%; value $401.4M; as of 2025-12-31.

Centessa Pharmaceuticals plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
JNJ Johnson & Johnson 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
GMAB Genmab A/S 100.00 2
BOLT Bolt Biotherapeutics, Inc. 100.00 2
GHRS GH Research PLC 100.00 2
IMTX Immatics N.V. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
SNYNF Sanofi 50.00 2
GNMSF Genmab A/S 38.88 1 ['customer']
MGNX MacroGenics, Inc. 14.78 2